Citations

Clear

1053 citation(s) found for "Andre, F".

Abstract 1413: RUNX3 plays an oncogenic role in Ewing sarcoma cells
Bledsoe, Krista L., Oliveira, André M. , Wijnen, André J. van , McGee‐Lawrence, Meghan E. , Camilleri, Emily T. , Westendorf, Jennifer J. , van Wijnen, Andre J

Mayo Clinic

Cancer Research | May 1, 2015 | Volume: 74 | Issue: 19_Supplement | Pages: 1413-1413

10.1158/1538-7445.am2014-1413 Get It

Abstract Ewing sarcomas are aggressive, poorly differentiated pediatric tumors of bone and soft tissue. Ewing sarcoma affects one to three people per million every year and is the second most common pediatric bone malignancy after osteosarcoma. Approximately 85% of Ewing sarcomas harbor the EWS-FLI fusion protein, which arises from a chromosomal translocation, t(11:22)(q24:q12). EWS-FLI interacts with numerous lineage-essential transcription factors to maintain mesenchymal progenitors in an undifferentiated state. We previously showed that EWS-FLI binds the osteogenic transcription factor RUNX2, and prevents osteoblast differentiation. RUNX3 is highly homologous to RUNX2 and participates in the mesenchymal-derived bone formation. RUNX3 has been described as both a tumor suppressor and an oncogene in different tumor types. In this study, we investigated the role of RUNX3 in Ewing Sarcoma. RUNX3 was detected in all Ewing sarcoma cells examined (7/7 cell lines, and 4/4 primary tumors), whereas RUNX2 was detected in only 73% of these specimens. Immunoprecipitation experiments revealed that RUNX3 binds to EWS-FLI via its Runt domain, which is >91% identical to the Runt domain in RUNX2. The interaction between RUNX3 and EWS-FLI in cell nuclei was confirmed by immunofluorescence. Moreover, EWS-FLI interactions prevented RUNX3 from activating the transcription of a RUNX-responsive reporter, p6OSE2. To determine the role of RUNX3 in Ewing sarcoma cell growth, we stably suppressed RUNX3 expression in the Ewing sarcoma cell line A673 with shRNAs. In anchorage independent growth assays in soft agar, RUNX3-deficient A673 cells formed smaller colonies than cells expressing scrambled shRNAs. Consistent with the smaller colonies, RUNX3 suppressed cells had increased expression of the cyclin dependent kinase inhibitor p21. Taken together, these results suggest and oncogenic role for RUNX3 in Ewing sarcoma. Citation Format: Krista L. Bledsoe, Meghan E. McGee-Lawrence, Emily T. Camilleri, Andre M. Oliveira, Andre J. van Wijnen, Jennifer J. Westendorf. RUNX3 plays an oncogenic role in Ewing sarcoma cells. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1413. doi:10.1158/1538-7445.AM2014-1413
Longer‐term follow‐up and outcome by tumour cell proliferation rate (Ki‐67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL‐001(EMERGE) pivotal trial
Beşışık, Sevgi Kalayoğlu , Drach, Johannes, Ramchandren, Radhakrishnan , Avivi, Irit , Rowe, Jacob M. , Herbrecht, Raoul , Hoof, Achiel Van, Zhang, Lei , Cicero, Sherri, Goy, Andre Henri , Robertson, Michael J. , Fu, Tommy , Witzig, Thomas E.

Mayo Clinic

British Journal of Haematology | April 29, 2015 | Volume: 170 | Issue: 4 | Pages: 496-503

10.1111/bjh.13456 | PMID 25921098 Get It

SummaryPatients with mantle cell lymphoma (MCL) generally respond to first‐line immunochemotherapy, but often show chemoresistance upon subsequent relapses, with poor outcome. Several studies of the immunomodulator, lenalidomide, have demonstrated its activity in MCL including the MCL‐001 study in relapsed/refractory patients who had failed defined prior therapies of anthracyclines or mitoxantrone, cyclophosphamide, rituximab and also bortezomib. We present here the long‐term efficacy follow‐up of the prospective phase II MCL‐001 study (N = 134), including new exploratory analyses with baseline Ki‐67 (MIB1), a biological marker of tumour proliferation. With longer follow‐up, lenalidomide showed a 28% overall response rate [ORR; 8% complete response (CR)/CR unconfirmed (CRu)]. Median duration of response (DOR), progression‐free survival and overall survival were 16·6, 4·0 and 20·9 months, respectively. Myelosuppression continued to be the most common grade 3/4 toxicity. Several studies of MCL patients treated with chemotherapy, rituximab and bortezomib have shown an inverse association between survival and Ki‐67. Ki‐67 data in 81/134 MCL‐001 patients showed similar ORRs in both low (<30% or <50%) versus high (≥30% or ≥50%) Ki‐67–expressing groups, yet lower Ki‐67 levels demonstrated superior CR/CRu, DOR and survival outcomes. Overall, lenalidomide showed durable efficacy with a consistent safety profile in heavily pretreated, relapsed/refractory MCL post‐bortezomib.
MicroRNA Levels as Prognostic Markers for the Differentiation Potential of Human Mesenchymal Stromal Cell Donors
Georgi, Nicole, Taipaleenmäki, Hanna , Raiss, C.C., Gröen, Nathalie , Portalska, Karolina Janaeczek, Boer, Jan de , Post, Janine N. , Wijnen, André J. van , Karperien, Marcel , van Wijnen, Andre J, Portalska, Karolina Janeczek, Blitterswijk, Clemens van , van Wijnen, Andre J

Mayo Clinic

Stem Cells and Development | April 27, 2015 | Volume: 24 | Issue: 16 | Pages: 1946-1955

10.1089/scd.2014.0534 | PMID 25915705 Get It

RETRACTED: Development of an Experimental Animal Model for Lower Back Pain by Percutaneous Injury‐Induced Lumbar Facet Joint Osteoarthritis
Ahmadinia, Kasra, Hamilton, John L. , Andrews, Steven W., Haralampus, Chris A., Xiao, Guozhi , Sohn, Hong‐Moon, You, Jae‐Won, Seo, Yo‐Seob, Stein, Gary S., Wijnen, André J. van , Kim, Su‐Gwan, Im, Hee‐Jeong, van Wijnen, Andre J, Kim, Jae‐Sung , Li, Xin , Sohn, Hong Moon , You, Jae Won , Im, Hee‐Jeong , van Wijnen, Andre J , Hamilton, John

Mayo Clinic

Journal of Cellular Physiology | April 9, 2015 | Volume: 230 | Issue: 11 | Pages: 2837-2847

10.1002/jcp.25015 | PMID 25858171 Get It

We report generation and characterization of pain‐related behavior in a minimally invasive facet joint degeneration (FJD) animal model in rats. FJD was produced by a non‐open percutaneous puncture‐induced injury on the right lumbar FJs at three consecutive levels. Pressure hyperalgesia in the lower back was assessed by measuring the vocalization response to pressure from a force transducer. After hyperalgesia was established, pathological changes in lumbar FJs and alterations of intervertebral foramen size were assessed by histological and imaging analyses. To investigate treatment options for lumber FJ osteoarthritis‐induced pain, animals with established hyperalgesia were administered with analgesic drugs, such as morphine, a selective COX‐2 inhibitor, a non‐steroidal anti‐inflammatory drug (NSAID) (ketorolac), or pregabalin. Effects were assessed by behavioral pain responses. One week after percutaneous puncture‐induced injury of the lumbar FJs, ipsilateral primary pressure hyperalgesia developed and was maintained for at least 12 weeks without foraminal stenosis. Animals showed decreased spontaneous activity, but no secondary hyperalgesia in the hind paws. Histopathological and microfocus X‐ray computed tomography analyses demonstrated that the percutaneous puncture injury resulted in osteoarthritis‐like structural changes in the FJs cartilage and subchondral bone. Pressure hyperalgesia was completely reversed by morphine. The administration of celecoxib produced moderate pain reduction with no statistical significance while the administration of ketorolac and pregabalin produced no analgesic effect on FJ osteoarthritis‐induced back pain. Our animal model of non‐open percutanous puncture‐induced injury of the lumbar FJs in rats shows similar characteristics of low back pain produced by human facet arthropathy. J. Cell. Physiol. 9999: 2837–2847, 2015. © 2015 Wiley Periodicals, Inc.
Molecular characterization of epithelioid haemangioendotheliomas identifies novel WWTR1–CAMTA1 fusion variants
Patel, Nimesh R, Salim, Alaa A. , Sayeed, Hadi, Sarabia, Stephen F. , Hollingsworth, Faith, Warren, Mikako , Jakacky, Jared, Tanas, Munir R. , Oliveira, André M. , Lazar, Alexander J. , López‐Terrada, Dolores , Wang, Wei‐Lien , Patel, Nimesh R. , Patel, Nimesh R, Rubin, Brian P. , Lazar, Alexander J

Mayo Clinic

Histopathology | March 27, 2015 | Volume: 67 | Issue: 5 | Pages: 699-708

10.1111/his.12697 | PMID 25817592 Get It

AimsEpithelioid haemangioendothelioma (EHE) is a malignant vascular neoplasm. Subsets have been characterized previously by translocations resulting in either WWTR1–CAMTA1 or YAP1–TFE3 fusion. We sought to develop molecular and immunohistochemical (IHC) assays to aid in the diagnosis and characterization of EHE.Methods and resultsFifty‐two formalin‐fixed, paraffin‐embedded (FFPE) cases diagnosed between 2002 and 2014 were retrieved from the pathology files of our institutions. Reverse transcription–polymerase chain reaction (RT–PCR) assays were optimized to detect WWTR1–CAMTA1 and YAP1–TFE3 fusion transcripts in FFPE tissue and transcription factor E3 (TFE3) protein accumulation was examined by immunohistochemistry (IHC). RNA was extracted from 33 adequate samples, with more recent cases providing a greater yield of high quality RNA. Fourteen of 18 informative cases were positive for WWTR1–CAMTA1 fusion transcripts, four of which showed higher‐grade cytological features termed by some as ‘malignant EHE’. Novel in‐frame fusion transcripts were identified in four cases by direct sequencing. IHC revealed variable nuclear TFE3 staining in six of 17 cases; three with patchy staining showed WWTR1–CAMTA1 fusion. One of 18 informative cases was positive for YAP1–TFE3 fusion and showed strong nuclear TFE3 staining by IHC.ConclusionsThis study confirms the high incidence of WWTR1–CAMTA1 and YAP1–TFE3 rearrangements in EHE and indicates that the staining pattern for TFE3 IHC is critical for specificity.
The SWI/SNF ATPases Are Required for Triple Negative Breast Cancer Cell Proliferation
Wu, Qiong , Madany, Pasil, Akech, Jacqueline, Dobson, Jason R. , Douthwright, Stephen, Browne, Gillian , Colby, Jennifer L., Bradner, James E. , Pratap, Jitesh , Sluder, Greenfield, Chiosea, Simion I. , Wijnen, André J. van , Stein, Janet L. , Stein, Gary S., Lian, Jane B. , Nickerson, Jeffrey A. , Imbalzano, Anthony N. , van Wijnen, Andre J, Winter, Georg E. , Bhargava, Rohit , van Wijnen, Andre J

Mayo Clinic

Journal of Cellular Physiology | March 24, 2015 | Volume: 230 | Issue: 11 | Pages: 2683-2694

10.1002/jcp.24991 | PMID 25808524 Get It

The Brahma (BRM) and Brahma‐related Gene 1 (BRG1) ATPases are highly conserved homologs that catalyze the chromatin remodeling functions of the multi‐subunit human SWI/SNF chromatin remodeling enzymes in a mutually exclusive manner. SWI/SNF enzyme subunits are mutated or missing in many cancer types, but are overexpressed without apparent mutation in other cancers. Here, we report that both BRG1 and BRM are overexpressed in most primary breast cancers independent of the tumor's receptor status. Knockdown of either ATPase in a triple negative breast cancer cell line reduced tumor formation in vivo and cell proliferation in vitro. Fewer cells in S phase and an extended cell cycle progression time were observed without any indication of apoptosis, senescence, or alterations in migration or attachment properties. Combined knockdown of BRM and BRG1 showed additive effects in the reduction of cell proliferation and time required for completion of cell cycle, suggesting that these enzymes promote cell cycle progression through independent mechanisms. Knockout of BRG1 or BRM using CRISPR/Cas9 technology resulted in the loss of viability, consistent with a requirement for both enzymes in triple negative breast cancer cells. J. Cell. Physiol. 9999: 2683–2694, 2015. © 2015 Wiley Periodicals, Inc.
Runx1 is associated with breast cancer progression in MMTV‐PyMT transgenic mice and its depletion in vitro inhibits migration and invasion
Browne, Gillian , Taipaleenmäki, Hanna , Bishop, Nicole , Madasu, Sharath C. , Shaw, Leslie M., Wijnen, André J. van , Stein, Janet L. , Lian, Jane B. , van Wijnen, Andre J, Shaw, Leslie M., Stein, Gary S. , van Wijnen, Andre J

Mayo Clinic

Journal of Cellular Physiology | March 20, 2015 | Volume: 230 | Issue: 10 | Pages: 2522-2532

10.1002/jcp.24989 | PMID 25802202 Get It

Runx1 is a transcription factor essential for definitive hematopoiesis, and genetic abnormalities in Runx1 cause leukemia. Runx1 is functionally promiscuous and acts as either an oncogene or tumor suppressor gene in certain epithelial cancers. Recent evidence suggests that Runx1 is an important factor in breast cancer, however, its role remains ambiguous. Here, we addressed whether Runx1 has a specific pathological role during breast cancer progression and show that Runx1 has an oncogenic function. We observed elevated Runx1 expression in a subset of human breast cancers. Furthermore, throughout the course of disease progression in a classical mouse model of breast cancer (i.e., the MMTV‐PyMT transgenic model), Runx1 expression increases in the primary site (mammary gland) and is further upregulated in tumors and distal lung metastatic lesions. Ex vivo studies using tumor epithelial cells derived from these mice express significantly higher levels of Runx1 than normal mammary epithelial cells. The tumor cells exhibit increased rates of migration and invasion, indicative of an aggressive cancer phenotype. Inhibition of Runx1 expression using RNA interference significantly abrogates these cancer‐relevant phenotypic characteristics. Importantly, our data establish that Runx1 contributes to murine mammary tumor development and malignancy and potentially represents a key disease‐promoting and prognostic factor in human breast cancer progression and metastasis. J. Cell. Physiol. 230: 2522–2532, 2015. © 2015 Wiley Periodicals, Inc.
Knockout of Kir6.2 negates ischemic preconditioning-induced protection of myocardial energetics
Gumina, Richard J. , Pucar, Darko , Bast, Peter, Hodgson, Denice M., Kurtz, Christopher E., Dzeja, Petras P. , Seino, Susumu , Miki, Takashi , Terzic, André

Mayo Clinic

American Journal of Physiology-Heart and Circulatory Physiology | March 3, 2015 | Volume: 284 | Issue: 6 | Pages: H2106-H2113

10.1152/ajpheart.00057.2003 | PMID 12598229 Get It

Although ischemic preconditioning induces bioenergetic tolerance and thereby remodels energy metabolism that is crucial for postischemic recovery of the heart, the molecular components associated with preservation of cellular energy production, transfer, and utilization are not fully understood. Here myocardial bioenergetic dynamics were assessed by18O-assisted31P-NMR spectroscopy in control or preconditioned hearts from wild-type (WT) or Kir6.2-knockout (Kir6.2-KO) mice that lack metabolism-sensing sarcolemmal ATP-sensitive K+(KATP) channels. In WT vs. Kir6.2-KO hearts, preconditioning induced a significantly higher total ATP turnover (232 ± 20 vs. 155 ± 15 nmol · mg protein−1· min−1), ATP synthesis rate (58 ± 3 vs. 46 ± 3%18O labeling of γ-ATP), and ATP consumption rate (51 ± 4 vs. 31 ± 4%18O labeling of Pi) after ischemia-reperfusion. Moreover, preconditioning preserved cardiac creatine kinase-catalyzed phosphotransfer in WT (234 ± 26 nmol · mg protein−1· min−1) but not Kir6.2-KO (133 ± 18 nmol · mg protein−1· min−1) hearts. In contrast with WT hearts, preconditioning failed to preserve contractile recovery in Kir6.2-KO hearts, as tight coupling between postischemic performance and high-energy phosphoryl transfer was compromised in the KATP-channel-deficient myocardium. Thus intact KATPchannels are integral in ischemic preconditioning-induced protection of cellular energetic dynamics and associated cardiac performance.
Targeting nucleotide-requiring enzymes: implications for diazoxide-induced cardioprotection
Dzeja, Petras P. , Bast, Peter, Özcan, Cevher , Valverde, Arturo M. , Holmuhamedov, Ekhson , Wylen, David G. L. Van, Terzic, André

Mayo Clinic

American Journal of Physiology-Heart and Circulatory Physiology | March 3, 2015 | Volume: 284 | Issue: 4 | Pages: H1048-H1056

10.1152/ajpheart.00847.2002 | PMID 12666660 Get It

Modulation of mitochondrial respiratory chain, dehydrogenase, and nucleotide-metabolizing enzyme activities is fundamental to cellular protection. Here, we demonstrate that the potassium channel opener diazoxide, within its cardioprotective concentration range, modulated the activity of flavin adenine dinucleotide-dependent succinate dehydrogenase with an IC50of 32 μM and reduced the rate of succinate-supported generation of reactive oxygen species (ROS) in heart mitochondria. 5-Hydroxydecanoic fatty acid circumvented diazoxide-inhibited succinate dehydrogenase-driven electron flow, indicating a metabolism-dependent supply of redox equivalents to the respiratory chain. In perfused rat hearts, diazoxide diminished the generation of malondialdehyde, a marker of oxidative stress, which, however, increased on diazoxide washout. This effect of diazoxide mimicked ischemic preconditioning and was associated with reduced oxidative damage on ischemia-reperfusion. Diazoxide reduced cellular and mitochondrial ATPase activities, along with nucleotide degradation, contributing to preservation of myocardial ATP levels during ischemia. Thus, by targeting nucleotide-requiring enzymes, particularly mitochondrial succinate dehydrogenase and cellular ATPases, diazoxide reduces ROS generation and nucleotide degradation, resulting in preservation of myocardial energetics under stress.
Adenylate kinase AK1 knockout heart: energetics and functional performance under ischemia-reperfusion
Pucar, Darko , Bast, Peter, Gumina, Richard J. , Lim, Lynette , DRAHL, CARMEN, Juranić, Nenad, Janssen, Edwin, Wieringa, Bé , Dzeja, Petras P. , Macura, Slobodan , Terzic, André

Mayo Clinic

American Journal of Physiology-Heart and Circulatory Physiology | March 3, 2015 | Volume: 283 | Issue: 2 | Pages: H776-H782

10.1152/ajpheart.00116.2002 | PMID 12124227 Get It

Deletion of the major adenylate kinase AK1 isoform, which catalyzes adenine nucleotide exchange, disrupts cellular energetic economy and compromises metabolic signal transduction. However, the consequences of deleting the AK1 gene on cardiac energetic dynamics and performance in the setting of ischemia-reperfusion have not been determined. Here, at the onset of ischemia, AK1 knockout mice hearts displayed accelerated loss of contractile force compared with wild-type controls, indicating reduced tolerance to ischemic stress. On reperfusion, AK1 knockout hearts demonstrated reduced nucleotide salvage, resulting in lower ATP, GTP, ADP, and GDP levels and an altered metabolic steady state associated with diminished ATP-to-Piand creatine phosphate-to-Piratios. Postischemic AK1 knockout hearts maintained ∼40% of β-phosphoryl turnover, suggesting increased phosphotransfer flux through remaining adenylate kinase isoforms. This was associated with sustained creatine kinase flux and elevated cellular glucose-6-phosphate levels as the cellular energetic system adapted to deletion of AK1. Such metabolic rearrangements, along with sustained ATP-to-ADP ratio and total ATP turnover rate, maintained postischemic contractile recovery of AK1 knockout hearts at wild-type levels. Thus deletion of the AK1 gene reveals that adenylate kinase phosphotransfer supports myocardial function on initiation of ischemic stress and safeguards intracellular nucleotide pools in postischemic recovery.